A Study to Evaluate the Safety and Pharmacokinetics of Multiple Doses Upadacitinib, Tofacitinib, and Baricitinib in Healthy Adult Volunteers

Part of paid clinical trials in Grayslake, Illinois.

Sponsor
AbbVie
Study ID
NCT07843693
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Healthy Volunteers

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Accepted

Interventions

Study Details

This is a Phase 1, open label, five arm study to evaluate the pharmacodynamic effects of multiple doses of upadacitinib, tofacitinib, and baricitinib in healthy adult participants.

Key Dates

First listed
Sep 28, 2026
Start date
Aug 26, 2026
Status verified
Sep 2026
Primary completion
Dec 31, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
60 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Arm 1: Multiple doses of Upadacitinib
    Upadacitinib will be administered once daily
  • Experimental: Arm 2: Multiple doses of Tofacitinib
    Tofacitinib will be administered twice daily
  • Experimental: Arm 3: Multiple doses of Upadacitinib
    Upadacitinib will be administered once daily
  • Experimental: Arm 4: Multiple doses of Tofacitinib
    Tofacitinib will be administered twice daily
  • Experimental: Arm 5: Multiple doses of Baricitinib
    Baricitinib will be administered once daily

Primary Outcome Measure

Number of Participants With Treatment Emergent Adverse Events (TEAE) [ Time Frame: Up to 44 Days ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Acpru /Id# 286751GrayslakeIllinois60030-

Find similar trials in Grayslake, IL

By research site
Acpru· Grayslake, IL

Related Studies